MX2020005615A - Composiciones de cromolín y métodos de las mismas. - Google Patents

Composiciones de cromolín y métodos de las mismas.

Info

Publication number
MX2020005615A
MX2020005615A MX2020005615A MX2020005615A MX2020005615A MX 2020005615 A MX2020005615 A MX 2020005615A MX 2020005615 A MX2020005615 A MX 2020005615A MX 2020005615 A MX2020005615 A MX 2020005615A MX 2020005615 A MX2020005615 A MX 2020005615A
Authority
MX
Mexico
Prior art keywords
methods
cromolyn
compositions
cromolyn compositions
packs
Prior art date
Application number
MX2020005615A
Other languages
English (en)
Spanish (es)
Inventor
David R Elmaleh
Original Assignee
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/830,980 external-priority patent/US10525005B2/en
Application filed by Massachusetts Gen Hospital filed Critical Massachusetts Gen Hospital
Publication of MX2020005615A publication Critical patent/MX2020005615A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
MX2020005615A 2017-12-04 2017-12-28 Composiciones de cromolín y métodos de las mismas. MX2020005615A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/830,980 US10525005B2 (en) 2013-05-23 2017-12-04 Cromolyn compositions and methods thereof
PCT/US2017/064526 WO2019112552A1 (en) 2017-12-04 2017-12-28 Cromolyn compositions and methods thereof

Publications (1)

Publication Number Publication Date
MX2020005615A true MX2020005615A (es) 2020-11-25

Family

ID=66751145

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005615A MX2020005615A (es) 2017-12-04 2017-12-28 Composiciones de cromolín y métodos de las mismas.

Country Status (8)

Country Link
EP (1) EP3720429A4 (ja)
JP (1) JP2021505658A (ja)
KR (1) KR20200096567A (ja)
CN (1) CN111629719A (ja)
AU (1) AU2017442079A1 (ja)
CA (1) CA3084593A1 (ja)
MX (1) MX2020005615A (ja)
WO (1) WO2019112552A1 (ja)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2466863A1 (en) * 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid
EP3563849A3 (en) * 2012-10-25 2020-02-12 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
EP2999337A4 (en) * 2013-05-23 2017-03-15 Aztherapies, Inc Methods for delivering cromolyn
EP3060205A4 (en) * 2013-10-22 2017-06-28 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US10265296B2 (en) * 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
AU2016359674A1 (en) * 2015-11-23 2018-06-14 The General Hospital Corporation Compositions and methods for treating ischemic stroke

Also Published As

Publication number Publication date
AU2017442079A1 (en) 2020-06-25
KR20200096567A (ko) 2020-08-12
JP2021505658A (ja) 2021-02-18
CA3084593A1 (en) 2019-06-13
EP3720429A1 (en) 2020-10-14
CN111629719A (zh) 2020-09-04
WO2019112552A1 (en) 2019-06-13
EP3720429A4 (en) 2021-09-15

Similar Documents

Publication Publication Date Title
MX2020013362A (es) Metodos para la liberacion de cromolina.
CY1122344T1 (el) Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
MX2015002371A (es) Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos.
EP3349783C0 (en) COMPOSITIONS AND METHODS ASSOCIATED WITH THE TREATMENT OF DISEASES
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX2021007268A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
IL273959A (en) Methods and preparations for the treatment of rare diseases
MX2023008211A (es) Composiciones y metodos para disminuir la expresion de tau.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
PH12017500217B1 (en) Anti-orai1 antibody
MX2014014443A (es) Agentes de ligacion a tlr3.
PH12015502564A1 (en) Pyridone derivatives for the treatment of viral infections and further diseases
EP3597198A4 (en) COMPOSITION FOR TREATMENT OF JOINT DISEASES AND KIT WITH IT
MX2020005615A (es) Composiciones de cromolín y métodos de las mismas.
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
EP3597199A4 (en) COMPOSITION FOR THE TREATMENT OF JOINT DISEASES, AND KIT CONTAINING THIS COMPOSITION
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations
SG11201911732TA (en) Cell composition, method of production and its use in corneal diseases
AU2016349439A8 (en) Non-bioconvertible C3-substituted pregnenolone derivatives for use in the treatment of substance use disorders
GB201516303D0 (en) Compositions and methods relating to the treatment of diseases